long intergenic non-protein coding RNA 1962Genealiases: []
Q-omics provides the consensus-scored LINC01962 profile across patient tissues and cancer cell-line models. LINC01962 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC01962 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, LINC01962 RNA expression shows 8,348 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LUAD, and KIRC as cancer lineages where LINC01962 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01962 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01962 survival associations across molecular data types. LINC01962 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01962 RNA expression–survival associations across cancer types. High LINC01962 expression shows unfavorable associations in LUAD and THCA, but favorable associations in MESO, PAAD, KIRC and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC01962 RNA expression.
This table summarizes LINC01962 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01962. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01962 shows lower tumor expression in COAD and higher tumor expression in KIRC, KIRP and LIHC. The KIRC box plot shows higher LINC01962 RNA expression in tumor versus normal tissue (log2 FC = +0.102, t-test p = .014).
This table shows molecular features associated with LINC01962 in patient tissues and cancer cell lines. In patient samples, LINC01962 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
